PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
 
Br J Cancer. 1994 August; 70(2): 346–351.
PMCID: PMC2033483

Frequent mutations of p53 gene in oesophageal squamous cell carcinomas with and without human papillomavirus (HPV) involvement suggest the dominant role of environmental carcinogens in oesophageal carcinogenesis.

Abstract

Epidemiological evidence suggests that alcohol intake, use of tobacco, ingestion of mycotoxins and nitrosamines and nutritional deficiencies are high-risk factors for the development of oesophageal cancer. Similarly, viral infections have been postulated to play a role in some tumours. However, the molecular events underlying the development of oesophageal carcinoma are poorly understood as yet. Loss of p53 tumour-suppressor gene function has been found in different human malignancies, and it can occur in a variety of ways, including gene mutation and interaction with the E6 protein of oncogenic human papillomaviruses (HPVs). Because the oesophageal mucosa is potentially exposed to mutagens and HPVs, we studied DNA samples derived from nine HPV-positive squamous cell carcinomas and 12 HPV-negative tumours. Exons 5-9 of the p53 gene containing phylogenetically conserved domains were examined using the polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) technique. HPV detection was done using DNA in situ hybridisation with biotin-labelled HPV DNA probes. Mutations were detected in eight (38%) out of the 21 cases. Three mutations were found in exons 5/6, three in exon 7 and two in exon 8/9. Six (50%) of the 12 HPV-negative carcinomas showed p53 mutations. Two (22.2%) of the nine HPV-positive carcinomas were found to contain p53 mutations as well; one contained HPV 16 DNA sequences and showed p53 mutation in exon 8/9, and the other was HPV 6/11 positive with the mutation in exon 5/6. Although mutations were more common in HPV-negative tumours (50.0% vs 22.2%), the difference in p53 mutations in HPV-positive and -negative tumours did not reach statistical significance (P = 0.1946). These data indicate that inactivation of the p53 gene is a frequent event in oesophageal squamous cell carcinomas and such an inactivation might be an important molecular pathway for the development of oesophageal cancer. The findings of p53 mutations in HPV-positive oesophageal carcinomas suggest that HPV and p53 mutation were not mutually exclusive events. The presence of frequent mutations of p53 gene in both HPV-positive and -negative oesophageal carcinomas suggests a dominant role of environmental carcinogens in oesophageal carcinogenesis.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.2M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Benamouzig R, Pigot F, Quiroga G, Validire P, Chaussade S, Catalan F, Couturier D. Human papillomavirus infection in esophageal squamous-cell carcinoma in western countries. Int J Cancer. 1992 Feb 20;50(4):549–552. [PubMed]
  • Bennett WP, Hollstein MC, He A, Zhu SM, Resau JH, Trump BF, Metcalf RA, Welsh JA, Midgley C, Lane DP, et al. Archival analysis of p53 genetic and protein alterations in Chinese esophageal cancer. Oncogene. 1991 Oct;6(10):1779–1784. [PubMed]
  • Bennett WP, Hollstein MC, Metcalf RA, Welsh JA, He A, Zhu SM, Kusters I, Resau JH, Trump BF, Lane DP, et al. p53 mutation and protein accumulation during multistage human esophageal carcinogenesis. Cancer Res. 1992 Nov 1;52(21):6092–6097. [PubMed]
  • Blount PL, Ramel S, Raskind WH, Haggitt RC, Sanchez CA, Dean PJ, Rabinovitch PS, Reid BJ. 17p allelic deletions and p53 protein overexpression in Barrett's adenocarcinoma. Cancer Res. 1991 Oct 15;51(20):5482–5486. [PubMed]
  • Boynton RF, Huang Y, Blount PL, Reid BJ, Raskind WH, Haggitt RC, Newkirk C, Resau JH, Yin J, McDaniel T, et al. Frequent loss of heterozygosity at the retinoblastoma locus in human esophageal cancers. Cancer Res. 1991 Oct 15;51(20):5766–5769. [PubMed]
  • Buchman VL, Chumakov PM, Ninkina NN, Samarina OP, Georgiev GP. A variation in the structure of the protein-coding region of the human p53 gene. Gene. 1988 Oct 30;70(2):245–252. [PubMed]
  • Casson AG, Mukhopadhyay T, Cleary KR, Ro JY, Levin B, Roth JA. p53 gene mutations in Barrett's epithelium and esophageal cancer. Cancer Res. 1991 Aug 15;51(16):4495–4499. [PubMed]
  • Chang F, Syrjänen S, Shen Q, Ji HX, Syrjänen K. Human papillomavirus (HPV) DNA in esophageal precancer lesions and squamous cell carcinomas from China. Int J Cancer. 1990 Jan 15;45(1):21–25. [PubMed]
  • Chang F, Syrjänen S, Shen Q, Wang L, Wang D, Syrjänen K. Human papillomavirus involvement in esophageal precancerous lesions and squamous cell carcinomas as evidenced by microscopy and different DNA techniques. Scand J Gastroenterol. 1992 Jul;27(7):553–563. [PubMed]
  • Chang F, Syrjänen S, Kurvinen K, Syrjänen K. The p53 tumor suppressor gene as a common cellular target in human carcinogenesis. Am J Gastroenterol. 1993 Feb;88(2):174–186. [PubMed]
  • Chang F, Syrjänen S, Tervahauta A, Syrjänen K. Tumourigenesis associated with the p53 tumour suppressor gene. Br J Cancer. 1993 Oct;68(4):653–661. [PMC free article] [PubMed]
  • Chang F, Syrjänen S, Syrjänen K. Demonstration of human papillomavirus (HPV) type 30 in esophageal squamous-cell carcinomas by in situ hybridization. Int J Cancer. 1993 Aug 19;55(1):171–173. [PubMed]
  • Chang F, Syrjänen S, Shen Q, Wang L, Syrjänen K. Screening for human papillomavirus infections in esophageal squamous cell carcinomas by in situ hybridization. Cancer. 1993 Nov 1;72(9):2525–2530. [PubMed]
  • Crook T, Wrede D, Vousden KH. p53 point mutation in HPV negative human cervical carcinoma cell lines. Oncogene. 1991 May;6(5):873–875. [PubMed]
  • DiPaolo JA, Woodworth CD, Popescu NC, Notario V, Doniger J. Induction of human cervical squamous cell carcinoma by sequential transfection with human papillomavirus 16 DNA and viral Harvey ras. Oncogene. 1989 Apr;4(4):395–399. [PubMed]
  • Frebourg T, Friend SH. Cancer risks from germline p53 mutations. J Clin Invest. 1992 Nov;90(5):1637–1641. [PMC free article] [PubMed]
  • Garrett LR, Perez-Reyes N, Smith PP, McDougall JK. Interaction of HPV-18 and nitrosomethylurea in the induction of squamous cell carcinoma. Carcinogenesis. 1993 Feb;14(2):329–332. [PubMed]
  • Harris CC. Chemical and physical carcinogenesis: advances and perspectives for the 1990s. Cancer Res. 1991 Sep 15;51(18 Suppl):5023s–5044s. [PubMed]
  • Hayashi K. PCR-SSCP: a method for detection of mutations. Genet Anal Tech Appl. 1992 Jun;9(3):73–79. [PubMed]
  • Hollstein MC, Metcalf RA, Welsh JA, Montesano R, Harris CC. Frequent mutation of the p53 gene in human esophageal cancer. Proc Natl Acad Sci U S A. 1990 Dec;87(24):9958–9961. [PubMed]
  • Hollstein MC, Peri L, Mandard AM, Welsh JA, Montesano R, Metcalf RA, Bak M, Harris CC. Genetic analysis of human esophageal tumors from two high incidence geographic areas: frequent p53 base substitutions and absence of ras mutations. Cancer Res. 1991 Aug 1;51(15):4102–4106. [PubMed]
  • Huang Y, Boynton RF, Blount PL, Silverstein RJ, Yin J, Tong Y, McDaniel TK, Newkirk C, Resau JH, Sridhara R, et al. Loss of heterozygosity involves multiple tumor suppressor genes in human esophageal cancers. Cancer Res. 1992 Dec 1;52(23):6525–6530. [PubMed]
  • Huang Y, Meltzer SJ, Yin J, Tong Y, Chang EH, Srivastava S, McDaniel T, Boynton RF, Zou ZQ. Altered messenger RNA and unique mutational profiles of p53 and Rb in human esophageal carcinomas. Cancer Res. 1993 Apr 15;53(8):1889–1894. [PubMed]
  • Hurlin PJ, Kaur P, Smith PP, Perez-Reyes N, Blanton RA, McDougall JK. Progression of human papillomavirus type 18-immortalized human keratinocytes to a malignant phenotype. Proc Natl Acad Sci U S A. 1991 Jan 15;88(2):570–574. [PubMed]
  • Iwasaka T, Oh-uchida M, Matsuo N, Yokoyama M, Fukuda K, Hara K, Fukuyama K, Hori K, Sugimori H. Correlation between HPV positivity and state of the p53 gene in cervical carcinoma cell lines. Gynecol Oncol. 1993 Jan;48(1):104–109. [PubMed]
  • Kulski J, Demeter T, Sterrett GF, Shilkin KB. Human papilloma virus DNA in oesophageal carcinoma. Lancet. 1986 Sep 20;2(8508):683–684. [PubMed]
  • Lane DP. Cancer. p53, guardian of the genome. Nature. 1992 Jul 2;358(6381):15–16. [PubMed]
  • Levine AJ. The p53 protein and its interactions with the oncogene products of the small DNA tumor viruses. Virology. 1990 Aug;177(2):419–426. [PubMed]
  • Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature. 1991 Jun 6;351(6326):453–456. [PubMed]
  • Li SL, Kim MS, Cherrick HM, Doniger J, Park NH. Sequential combined tumorigenic effect of HPV-16 and chemical carcinogens. Carcinogenesis. 1992 Nov;13(11):1981–1987. [PubMed]
  • Lu JB, Yang WX, Liu JM, Li YS, Qin YM. Trends in morbidity and mortality for oesophageal cancer in Linxian County, 1959-1983. Int J Cancer. 1985 Dec 15;36(6):643–645. [PubMed]
  • Meltzer SJ, Yin J, Huang Y, McDaniel TK, Newkirk C, Iseri O, Vogelstein B, Resau JH. Reduction to homozygosity involving p53 in esophageal cancers demonstrated by the polymerase chain reaction. Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4976–4980. [PubMed]
  • Miller C, Mohandas T, Wolf D, Prokocimer M, Rotter V, Koeffler HP. Human p53 gene localized to short arm of chromosome 17. Nature. 319(6056):783–784. [PubMed]
  • Orita M, Suzuki Y, Sekiya T, Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics. 1989 Nov;5(4):874–879. [PubMed]
  • Sarnow P, Ho YS, Williams J, Levine AJ. Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell. 1982 Feb;28(2):387–394. [PubMed]
  • Schmieg FI, Simmons DT. Characterization of the in vitro interaction between SV40 T antigen and p53: mapping the p53 binding site. Virology. 1988 May;164(1):132–140. [PubMed]
  • Syrjänen S, Partanen P, Mäntyjärvi R, Syrjänen K. Sensitivity of in situ hybridization techniques using biotin- and 35S-labeled human papillomavirus (HPV) DNA probes. J Virol Methods. 1988 Mar-Apr;19(3-4):225–238. [PubMed]
  • Toh Y, Kuwano H, Tanaka S, Baba K, Matsuda H, Sugimachi K, Mori R. Detection of human papillomavirus DNA in esophageal carcinoma in Japan by polymerase chain reaction. Cancer. 1992 Nov 1;70(9):2234–2238. [PubMed]
  • Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell. 1992 Aug 21;70(4):523–526. [PubMed]
  • Wagata T, Ishizaki K, Imamura M, Shimada Y, Ikenaga M, Tobe T. Deletion of 17p and amplification of the int-2 gene in esophageal carcinomas. Cancer Res. 1991 Apr 15;51(8):2113–2117. [PubMed]
  • Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science. 1990 Apr 6;248(4951):76–79. [PubMed]
  • Williamson AL, Jaskiesicz K, Gunning A. The detection of human papillomavirus in oesophageal lesions. Anticancer Res. 1991 Jan-Feb;11(1):263–265. [PubMed]
  • Winkler B, Capo V, Reumann W, Ma A, La Porta R, Reilly S, Green PM, Richart RM, Crum CP. Human papillomavirus infection of the esophagus. A clinicopathologic study with demonstration of papillomavirus antigen by the immunoperoxidase technique. Cancer. 1985 Jan 1;55(1):149–155. [PubMed]
  • zur Hausen H. Viruses in human cancers. Science. 1991 Nov 22;254(5035):1167–1173. [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK